Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Telix Pharmaceuticals ( (AU:TLX) ) has shared an announcement.
Telix Pharmaceuticals will release 47,256 ordinary shares from voluntary escrow on 31 January 2026, representing stock originally issued to Lightpoint Medical as part of the consideration for Telix’s acquisition of Lightpoint and its SENSEI radio-guided surgery business. The release marginally increases the tradeable free float of Telix shares and marks a further step in integrating the Lightpoint acquisition into Telix’s capital structure, though the relatively small volume suggests limited immediate market impact for existing shareholders.
The most recent analyst rating on (AU:TLX) stock is a Hold with a A$11.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a Melbourne-headquartered biopharmaceutical company specializing in therapeutic and diagnostic radiopharmaceuticals and related medical technologies, with a focus on addressing unmet medical needs in oncology and rare diseases. The company operates internationally across the United States, United Kingdom, Brazil, Canada, Europe and Japan, and is dual-listed on the ASX and Nasdaq under the ticker TLX.
Average Trading Volume: 1,907,280
Technical Sentiment Signal: Sell
Current Market Cap: A$3.89B
For a thorough assessment of TLX stock, go to TipRanks’ Stock Analysis page.